Companies › Iterion Therapeutics
1 active drug program in 7 registered trials: 7 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tegavivint Wnt signaling pathway inhibitor | – | Phase 1 | Advanced Hepatocellular Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Leukemia; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05797805 | Tegavivint | Phase 1 | Advanced Hepatocellular Carcinoma | Oncology | May 2026 |
| NCT04780568 | Tegavivint | Phase 1 | Metastatic Lung Non-Small Cell Carcinoma | Oncology | Dec 2026 |
| NCT04874480 | Tegavivint | Phase 1 | Recurrent Leukemia | Oncology | Feb 2027 |
| NCT05755087 | Tegavivint | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Oncology | Mar 2028 |
| NCT07144254 | Tegavivint | Phase 1 | Osteosarcoma Recurrent | Oncology | May 2028 |
| NCT04851119 | Tegavivint | Phase 1 | Colorectal Carcinoma | Oncology | Jun 2028 |
| NCT07463599 | Tegavivint | Phase 1 | Metastatic Colorectal Carcinoma (mCRC) | Oncology | Jan 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.